Arcutis Biotherapeutics Director Howard Welgus Exercises Options and Sells Shares Under 10b5-1 Plan

This Form 4 filing reports that Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc. (ARQT), exercised stock options and sold shares pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026. On June 15, 2026, Welgus exercised three sets of stock options totaling 4,096 shares at exercise prices ranging from $6.5223 to $8.63 per share, acquiring the underlying common stock. Simultaneously, he sold 4,096 shares at a weighted average price of $24.4093. Two days later on June 17, 2026, he sold an additional 635 shares at $25.67 per share. Following these transactions, Welgus holds 37,743 shares of common stock directly. The transactions were executed under a pre-established 10b5-1 plan, which provides an affirmative defense against insider trading allegations.